L3VLUP
ProSign in

SNY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SNYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SNY
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSNYVRTX
Q3 202011 holders, $3.4bn31 holders, $21.9bn
Q4 20207 holders, $3.3bn30 holders, $18.4bn
Q1 20217 holders, $4.5bn31 holders, $15.4bn
Q2 20215 holders, $4.9bn30 holders, $12.7bn
Q3 20217 holders, $6.0bn35 holders, $10.1bn
Q4 20217 holders, $6.2bn28 holders, $12.4bn
Q1 20227 holders, $6.5bn23 holders, $16.1bn
Q2 20227 holders, $6.1bn25 holders, $18.1bn
Q3 20229 holders, $4.6bn22 holders, $18.4bn
Q4 202210 holders, $5.9bn28 holders, $18.4bn
Q1 202312 holders, $6.6bn26 holders, $21.4bn
Q2 20239 holders, $6.1bn27 holders, $24.7bn
Q3 20239 holders, $5.9bn33 holders, $24.3bn
Q4 20237 holders, $5.3bn32 holders, $28.6bn
Q1 20247 holders, $5.1bn31 holders, $29.8bn
Q2 202411 holders, $5.5bn29 holders, $33.4bn
Q3 202411 holders, $6.5bn27 holders, $33.5bn
Q4 20248 holders, $5.1bn26 holders, $28.5bn
Q1 20258 holders, $6.2bn21 holders, $35.4bn
Q2 20257 holders, $4.8bn21 holders, $32.3bn
Q3 20256 holders, $3.8bn22 holders, $25.9bn
Q4 20256 holders, $3.0bn26 holders, $31.8bn
Q1 20266 holders, $1.7bn25 holders, $31.8bn
Q2 20267 holders, $1.6bn26 holders, $34.6bn
SNY

Sanofi

Holders
7
Reported value
$5.3bn
Buyers
4
Sellers
5

Breadth -1 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SNY (4)

Dodge & Cox, First Eagle Investment Management LLC, Point72 Asset Management LP, Soros Fund Management LLC

Only VRTX (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Hudson Bay Capital Management LP, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →